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TECHNICAL ADVANCE Open Access
Genomic data analysis workflows for
tumors from patient-derived xenografts
(PDXs): challenges and guidelines
Xing Yi Woo1†, Anuj Srivastava1†, Joel H. Graber3†, Vinod Yadav1,5, Vishal Kumar Sarsani2,4, Al Simons2, Glen Beane2,
Stephen Grubb2, Guruprasad Ananda1, Rangjiao Liu1,6, Grace Stafford2, Jeffrey H. Chuang1, Susan D. Airhart2,
R. Krishna Murthy Karuturi1, Joshy George1* and Carol J. Bult2*
Abstract
Background: Patient-derived xenograft (PDX) models are in vivo models of human cancer that have been used for
translational cancer research and therapy selection for individual patients. The Jackson Laboratory (JAX) PDX
resource comprises 455 models originating from 34 different primary sites (as of 05/08/2019). The models undergo
rigorous quality control and are genomically characterized to identify somatic mutations, copy number alterations,
and transcriptional profiles. Bioinformatics workflows for analyzing genomic data obtained from human tumors
engrafted in a mouse host (i.e., Patient-Derived Xenografts; PDXs) must address challenges such as discriminating
between mouse and human sequence reads and accurately identifying somatic mutations and copy number
alterations when paired non-tumor DNA from the patient is not available for comparison.
Results: We report here data analysis workflows and guidelines that address these challenges and achieve reliable
identification of somatic mutations, copy number alterations, and transcriptomic profiles of tumors from PDX
models that lack genomic data from paired non-tumor tissue for comparison. Our workflows incorporate commonly
used software and public databases but are tailored to address the specific challenges of PDX genomics data analysis
through parameter tuning and customized data filters and result in improved accuracy for the detection of somatic
alterations in PDX models. We also report a gene expression-based classifier that can identify EBV-transformed tumors.
We validated our analytical approaches using data simulations and demonstrated the overall concordance of the
genomic properties of xenograft tumors with data from primary human tumors in The Cancer Genome Atlas (TCGA).
Conclusions: The analysis workflows that we have developed to accurately predict somatic profiles of tumors from
PDX models that lack normal tissue for comparison enable the identification of the key oncogenic genomic and
expression signatures to support model selection and/or biomarker development in therapeutic studies. A reference
implementation of our analysis recommendations is available at https://github.com/TheJacksonLaboratory/PDX-
Analysis-Workflows.
Keywords: Patient-derived xenografts, DNA sequencing, RNA sequencing, SNP array, Somatic mutation, Gene
expression, Copy number alterations, Mouse stroma, Bioinformatic analysis
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Background
Patient-derived xenograft (PDX) models are in vivo
models of human cancer that have been used for transla-
tional cancer research and therapy selection for individ-
ual patients [1–8]. Previous studies have demonstrated
human tumors engrafted in mouse hosts retain thera-
peutically relevant genomic aberrations found in the ori-
ginal patient tumor [3, 9, 10] and that treatment
responses of tumor-bearing mice typically reflect the re-
sponses observed in patients [6, 11]. PDXs have been
used successfully as a platform for pre-clinical drug
screens [6, 7, 11], to facilitate the development of poten-
tial biomarkers of drug response and resistance [6, 7,
12], and to select appropriate therapeutic regimens for
individual patients [9].
The Jackson Laboratory (JAX) PDX resource comprises
455 PDX cancer models originating from 34 different pri-
mary sites (as of 05/08/2019, Table S14). The models
undergo rigorous quality control and are genomically
characterized to identify somatic mutations, copy number
alterations, and transcriptional profiles (Fig. 1). To date,
over 100 models in the resource have been assessed for
their response to cytotoxic and/or targeted therapeutic
agents. The integration of results from dosing studies with
genomic data for the models has been successfully applied
to the identification of novel genomic biomarkers associ-
ated with treatment responses [13].
Four major challenges need to be addressed to geno-
mically characterize human tumors engrafted in a mouse
host. First, mouse sequences must be removed from a
data set prior to data analysis. Nucleic acids extracted
from engrafted tumors include both mouse and human
sequences because human stroma is replaced by mouse
cells during tumor engraftment [14]. As the protein-
coding regions of the mouse and human genomes are
85% identical on average [15]; there is a high risk of
introducing false positive (FP) variants resulting from
mouse sequences aligning to a reference human genome
[16–18]. Second, a baseline normal must be created to
identify aberrations that are likely somatic. Paired nor-
mal samples are not available for the majority of JAX
PDXs because the tumor tissue used to create the
models was material that remained following clinical
pathology assessment (i.e., tumors were not collected
specifically for xenograft model creation). The absence
of genomic data from paired normal tissue complicates
the process of distinguishing germline variants from
somatic alterations (point mutations, indels, and copy
number alterations) in the tumor [19–22]. Third, sys-
tematic errors in sequencing and alignment can lead to
FP variant calls and require customized filtering logic in
computational workflows [23–25]. Finally, care must be
taken to ensure the engrafted tumors in PDXs match the
expected cancer type. Some strains of immunodeficient
host mice are susceptible to forming B-cell human
lymphomas during engraftment due to Epstein-Barr
virus (EBV)-associated lymphomagenesis [26–30]. Iden-
tifying PDX tumors that arise from EBV transformation
is critical to the model integrity and to meaningful gen-
omic data analysis.
Here we describe bioinformatics analysis workflows
and guidelines (https://github.com/TheJacksonLabora-
tory/PDX-Analysis-Workflows) that we developed spe-
cifically for the analysis of genomic data generated from
PDX tumors. Our workflows incorporate commonly
used software and public databases but are tailored to
address the specific challenges of PDX genomics data
analysis through parameter tuning and customized data
filters and result in improved accuracy for the detection
of somatic alterations in PDX models relative to analyses
that lacked custom filters. We also report a gene
expression-based classifier that can identify EBV-
transformed tumors. Finally, to demonstrate the effect-
iveness of our workflows, we show the overall concord-
ance of the genomic and transcriptomic profiles of the
PDX models in the JAX PDX resource with relevant
tumor types from The Cancer Genome Atlas (TCGA).
Methods
Genomic and transcriptomic profiling of engrafted
tumors
DNA sequencing
Flash frozen tissues were pulverized using a Bessman
Tissue Pulverizer (Spectrum Chemical) and homoge-
nized in Nuclei Lysis Buffer (Promega) using a gentle-
MACS dissociator (Miltenyi Biotec Inc). DNA was
isolated using the Wizard Genomic DNA Purification
Kit (Promega) according to manufacturer’s protocols.
DNA quality and concentration were assessed using a
Nanodrop 2000 spectrophotometer (Thermo Scientific),
a Qubit dsDNA BR Assay Kit on a Qubit Fluorometer
(Thermo Scientific), and the Genomic DNA ScreenTape
on a 4200 TapeStation (Agilent Technologies). Libraries
were prepared using the Hyper Prep Kit (KAPA Biosys-
tems) and SureSelectXT Target Enrichment System with
the JAX Cancer Treatment Profile (CTP) targeted panel
of 358 related genes (Agilent Technologies) [31, 32],
according to the manufacturer’s instructions. Briefly, the
protocol entails shearing the DNA using the Covaris
E220 Focused-ultrasonicator (Covaris), ligating Illumina
specific adapters, and PCR amplification. Amplified
DNA libraries are then hybridized to the CTP probes,
amplified using indexed primers, and checked for quality
and concentration using the High Sensitivity D5000
ScreenTape (Agilent Technologies) and Qubit dsDNA
HS Assay Kit (Thermo Scientific). Libraries were pooled
and sequenced 150 bp paired-end on the NextSeq 500
(Illumina) using NextSeq v2 reagents (Illumina).
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RNA sequencing
Tissues preserved in RNAlater were homogenized in
TRIzol (ThermoFisher Scientific) using a gentleMACS
dissociator (Miltenyi Biotec Inc). Total RNA was isolated
using the miRNeasy Mini kit (Qiagen) according to
manufacturer’s protocols, including the optional DNase
digest step. RNA quality and concentration were
assessed using the RNA 6000 Nano LabChip assay on
Fig. 1 Overview of Patient-Derived Xenograft (PDX) model generation and genomic characterization at The Jackson Laboratory (JAX). a Schematic overview
of PDX model generation and characterization for the JAX PDX resource. JAX has generated, clinically annotated, and genomically characterized 455 PDX
cancer models originating from 34 different primary sites (as of 05/08/2019) using the immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (aka, NSG™) mouse as
the host strain. b Schematic of the genomic characterization of PDX models (see Methods for details). The three primary genomic characterization methods
are: 1) somatic mutations using the JAX Cancer Treatment Profile™ (CTP, https://www.jax.org/clinical-genomics/clinical-offerings/jax-cancer-treatment-profile),
the Illumina TruSeq™ panel or whole-exome sequencing, 2) DNA copy-number variation using Affymetrix SNP 6.0 arrays, and 3) gene expression profiles from
Affymetrix microarrays or RNA sequencing (Illumina HiSeq)
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the 2100 Bioanalyzer instrument and Nanodrop 2000
spectrophotometer (Thermo Scientific). Prior to 2016,
non-stranded libraries were constructed using TruSeq
RNA Library Prep Kit v2 (Illumina). Stranded libraries
were prepared using the KAPA mRNA HyperPrep Kit
(KAPA Biosystems), according to the manufacturer’s in-
structions. Briefly, the protocol entails isolation of polyA
containing mRNA using oligo-dT magnetic beads, RNA
fragmentation, first and second strand cDNA synthesis,
ligation of Illumina-specific adapters containing a unique
barcode sequence for each library, and PCR amplifica-
tion. Libraries were checked for quality and concentra-
tion using the DNA 1000 assay (Agilent Technologies)
and quantitative PCR (KAPA Biosystems), according to
the manufacturers’ instructions. Libraries were pooled
and sequenced 75 bp paired-end on the NextSeq 500
(Illumina) using NextSeq High Output Kit v2 reagents
(Illumina), or 100 bp paired-end on the HiSeq2500 (Illu-
mina) using TruSeq SBS v3 reagents (Illumina).
SNP array
DNA samples were sent to the Genotyping Core at the
Hussman Institute for Human Genomics (University of
Miami) for genotyping on the Genome-Wide Human
SNP Array 6.0 (Affymetrix). Quality control on the CEL
files was carried out using the standard Contrast QC
metric from the Affymetrix Genome Wide SNP 6.0 array
manual.
Somatic point mutation and indel calling workflow
Preprocessing and removal of mouse reads
DNA sequence data generated from PDX tumors under-
went initial data processing as follows: (i) sequence reads
with 70% of the bases having a quality score < 30 (Q30)
were discarded, (ii) bases with quality scores less than
Q30 were trimmed from the 3′ end of the read, (iii) se-
quence reads with < 70% of bases remain after trimming
were discarded, (iv) both reads from pair-end sequencing
were discarded if either read was discarded. If < 50% of
the total reads remained following the preprocessing
steps, the sample was removed from the analysis. Fol-
lowing the initial data processing step described above,
mouse reads were identified and filtered out using
Xenome v1.0.0 [16]. Only read pairs with both reads
classified as human were included in further analyses.
Sequence reads that passed all pre-processing steps
were mapped to the reference human genome (build
GRCh38.p5 with 262 alternate loci) using the BWA-
MEM alignment tool with ALT-Aware mapping (Add-
itional file 1: Text S5) [33–35]. Because low sequence
coverage leads to poor sensitivity in variant calling, sam-
ples with less than 75% of the target region covered at
least at ≥100X by human reads were excluded from fur-
ther analysis.
Variant calling
The GATK best practices workflow (https://software.
broadinstitute.org/gatk/best-practices/) using the Uni-
fiedGenotyper, was used for variant discovery analysis
[36–38], which is comprised of the following steps: (i)
sorting the SAM/BAM file by coordinate, (ii) removing
duplicates to mitigate biases introduced by library prep-
aration steps such as PCR amplification by Picard
(https://broadinstitute.github.io/picard/), and (iii) recali-
brating the base quality scores as the variant calling al-
gorithms rely heavily on the quality scores assigned to
the individual base calls in each sequence read. Pindel
[39] was also incorporated into the workflow to call
indels that have been missed by the GATK
UnifiedGenotyper.
Quality filtering of variants for targeted sequencing
High quality variants from both variant callers in the PDX
samples were obtained based on GATK hard filtering (see
below), and have a read depth (DP) of ≥140 and allele fre-
quency (ALT_AF) of ≥5%. These DP and ALT_AF thresholds
were optimized using a set of known and validated mutations
and samples reported earlier for the JAX CTP targeted panel
sequencing at high coverage (average 941 X) [31, 32]. The
parameters for GATK hard filtering [40] were set as default
as recommended by GATK best practices (https://software.
broadinstitute.org/gatk/documentation/tooldocs/current/,
https://software.broadinstitute.org/gatk/best-practices/):
(i) for point mutations, QD < 2.0, FS > 60.0, MQ < 40.0,
MQRankSum < − 12.5, ReadPosRankSum < − 8.0.
(ii) for indels, QD < 2.0, FS > 200.0, ReadPosRankSum
< − 20.0.
In addition, we verified that these default thresholds
were able to detect all the known mutations in the CTP
samples [31]. The average number of variants before and
after quality filtering across the CTP samples is shown
Additional file 1: Table S4.
Annotation of variants
Variants were annotated for their effect (gene, conse-
quence, amino acid change, etc.) using SnpEff v4.3 [41]
based on gene annotations from Ensembl (version 84)
and information from COSMIC version 80 [42], dbSNP
build 144 [43]. The observed variant allele frequency in
the 1000 Genomes Project [44] and ExAC version 0.3
[31, 45] databases were obtained using SnpSift tool by
utilizing dbNSFP3.2a.txt database. We further annotated
each variant with 1) known or predicted gain or loss of
protein function, 2) potential treatment approach for
any cancer type and 3) drug sensitivity and resistance
effects in clinical or preclinical studies, based on curated
clinical information from the JAX clinical knowledge
base (CKB, https://ckbhome.jax.org/) [46, 47] via direct
integration of our internal database of PDX data with
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the JAX CKB database. The JAX CKB contains annota-
tions for 28,362 variants in 1320 genes (as of 05/03/
2019). The average number of variants annotated to be
clinically relevant across the CTP samples is shown in
Additional file 1: Table S4.
Filtering of germline variants
Since normal samples from patients whose tumors were
used to generate the PDX models were unavailable in
most cases, we generated a dataset of putative human
germline variants using data from several public re-
sources: (i) dbSNP, (ii) 1000 Genomes Project, (iii) ExAC
database with MAF ≥1%, and (iv) a compendium of vari-
ants from 20 normal human blood samples available in
JAX (Additional file 1: Text S1) that were prepped and
sequenced on the CTP panel using the same protocol as
the PDX samples, with a frequency of 2/20 in normal
samples or 1/20 in normal samples and 2/20 in PDX
models. The number of variants in each of these data-
bases are shown in Additional file 1: Table S3. The vari-
ants identified via GATK and Pindel in the PDX model
tumors were annotated as germline and filtered out of
the model’s somatic mutation calls if they were present
in our aggregated dataset of putative germline variants
and had allele frequencies between 40 to 60% or more
than 90%.
Filtering putative false positives
Variants not in our aggregated dataset of putative germ-
line variants described above but occurred at a frequency
of 25% or greater across all PDX models (n = 236) were
considered to be putative false positive (FP) mutations.
The rationale for this data filtering step was based on our
observation that the maximum recurrent frequency of
somatic mutated base positions was 6% across a compen-
dium of TCGA tumor samples (n = 3576, 9 tumor types
that were also represented in the PDX model). Thus, we
would expect that any mutated loci recurring across PDX
samples at significantly higher rates to likely be FP. Sys-
tematic technical errors in sequencing and/or mapping
are possible explanations for the common recurrent non-
somatic mutations identified PDX models.
Rescuing false negative variants
An exception to the germline and false positives exclu-
sion process was made for variants from GATK that
were annotated as clinically relevant in JAX CKB. We
rescued any filtered variants that were curated into the
proprietary JAX-Clinical Knowledgebase (CKB, https://
ckbhome.jax.org/) with 1) known or predicted gain or
loss of protein function, 2) potential treatment approach
for any cancer type and 3) drug sensitivity and resistance
effects in clinical or preclinical studies. In addition, as
Pindel results contained a large number of FPs, we only
included those that were present in the JAX-CKB by the
same criteria.
Benchmarking of PDX somatic mutation workflow
To benchmark the PDX somatic mutation workflow, we
generated simulated datasets for five PDX models and
nine conditions. The datasets included 1) varying se-
quencing coverage, 2) spiked-in mutations representative
of the different tumor types, and 3) different proportions
of spiked-in mouse sequence contamination (Add-
itional file 2: Table S1).
Generation of simulated sequence reads
SeqMaker was used to generate simulated sequencing data
based on human genome assembly GRCh38.5 with vary-
ing sequencing depth, read length, duplication rate, se-
quencing error and base quality range [48]. Reference
sequences were extracted from target region of the CTP
panel. Sequence reads for 5 PDX tumor samples were
simulated using predicted mutations from PDX models of
different cancer types from the CTP dataset to represent
different spectrum of mutations, with a range of allele fre-
quency to mimic germline and somatic mutations. For
each simulated sample, we generated three technical repli-
cates at 500X, 1000X and 1500X coverage.
Mouse sequencing reads were added in different frac-
tions to the human-specific simulated dataset to mimic
mouse contamination observed in PDX models. The
mouse reads were extracted from the sequencing data of
mouse DNA isolated from fresh spleen tissue of NSG
mice on the CTP. For each simulated human-specific
sample, we added mouse reads in three proportions (10,
15 and 25% of the total coverage).
Calculate sensitivity and specificity of mutation results
based on different workflow filters
To evaluate the effect of each filter used in our work-
flow, we modified the somatic mutation workflow by: (i)
omitting Xenome to filter mouse reads, and (ii) mapping
to the reference sequence using BWA-MEM. Each
modified workflow was used to process each PDX simu-
lated library and each set of results, with and without
quality filters, was used to compute the lists of true posi-
tive, false positive, true negative and false negative vari-
ants. As such, we can calculate the range of sensitivities
and specificities of the predicted variants for all the sim-
ulated PDX models. We compared the distributions of
precision, recall and F1-score (2*(Recall*Precision)/
(Recall+Precision)) for different variations of the variant
calling workflow on the simulated datasets. Furthermore,
we compared the predicted allele frequencies of the true
positives of each sample with the input by correlation.
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Gene expression workflow
Data processing and expression estimation
Prior to alignment to the human transcriptome,
sequences from PDX tumors were processed for se-
quence quality. Only sequences with base qualities
≥30 over 70% of read length were used in down-
stream analyses. Quality trimmed reads were then an-
alyzed using the default parameters of Xenome v1.0.0
(k = 25) [16] to separate human, mouse, and ambigu-
ous sequences (i.e., sequences that cannot be reliably
classified as mouse or human). Sequence reads that
passed the quality and Xenome screening were
aligned to a human transcriptome dataset (ENSEMBL
version 84) using Bowtie v2.2.0 [49, 50]. Only samples
with at least 1 million human reads were retained for
expression analysis to ensure reliable quantification of
gene expression level for all genes. The 1 million hu-
man read cutoff was determined using down-sampling
experiments (data not shown). Gene expression esti-
mates were determined using RSEM v1.2.19 [51]
(rsem-calculate-expression) with default parameters.
We further normalized the expression estimate (ex-
pected_count from RSEM) using upper quantile
normalization of non-zero expected counts and scal-
ing to 1000.
Classifier for EBV-associated PDX lymphomas
A gene signature for identifying putative EBV-
associated lymphomas was derived by calculating the
fold change of the average expression of the expressed
genes between 20 EBV-associated lymphomas and 100
non-EBV tumors based on the Z-score transformation
of upper-quantile normalized RNA-Seq counts (RSEM).
24 up-regulated and 24 downregulated genes, selected
based on the highest and lowest fold change values,
were used to define the list of classifier genes (Add-
itional file 1: Table S6). We further checked that the ex-
pression levels of these classifier genes were consistent
among the EBV-associated lymphomas, and were able
to cluster the EBV-associated lymphomas separately
from other non-lymphoma PDX tumors (Fig. S5). Gene
set analysis on the resulting expression vector was per-
formed with GSEA using the GenePattern webserver
and default parameters (data not shown). For each PDX
sample, the upper-quantile normalized counts from
RSEM of the classifier genes were transformed into z-
scores using the mean and standard deviation com-
puted across all PDX samples for each gene. Subse-
quently, a sign corresponding to the direction of
regulation in the classifier table was multiplied to each
z-score and the sum of these modified z-scores resulted
in a single score for each PDX sample. A classifier score
of > 3.0 was used to identify a PDX tumor sample as a
potential EBV-associated lymphoma.
Copy number alterations (CNA) workflow
Assessing the effects of mouse DNA on SNP array
DNA of the NSG mouse was hybridized on the Affyme-
trix SNP 6.0 array, and the signal intensity was extracted
from the CEL files using Affymetrix Power Tools (apt-
cel-extract). The mouse content for each PDX sample
was estimated by the mouse reads proportion computed
by Xenome of the mutation calling pipeline for the CTP
sequencing of the same PDX sample.
Single-tumor CNA analysis
PennCNV-Affy and Affymetrix Power Tools [52–54]
were used to extract the B-allele frequency (BAF) and
Log R Ratio (LRR) from the resulting CEL files of the
Affymetrix Human SNP 6.0 array. Due to the absence of
paired-normal samples, the allele-specific signal intensity
for each PDX tumor were normalized relative to 300
randomly selected sex-matched Affymetrix Human SNP
6.0 array samples obtained from the International Hap-
Map project [55]. The single tumor version of ASCAT
2.4.3 [56], which could infer the necessary germline
genotypes from the tumor data, was then used for GC
correction, predictions of the heterozygous germline
SNPs and estimation of ploidy, tumor content and copy
number segments with allele-specific copy number.
Tumor-normal CNA analysis
The same normalization steps as the single-tumor ana-
lysis were applied in which both tumor and normal CEL
files were normalized with 300 HapMap samples,
followed by the CNA analysis using the tumor-normal
version of ASCAT 2.4.3.
Annotation of CNA segments
The resultant copy number segments were annotated
with loss of heterozygosity (LOH) and log2 ratio of total
copy number relative to diploid state (copy number 2)
and predicted ploidy from ASCAT. A segment was de-
fined as LOH when the major-allele copy number was
≥0.5 and the minor-allele copy number was ≤0.1. Gene-
level copy number and LOH were estimated by inter-
secting the genome coordinates of copy number
segments with genome coordinates of genes (Ensembl
version 84; genome assembly GRCh38.5). In cases where
a segment boundary was contained within a gene’s coor-
dinates, the most conservative (lowest) estimate of copy
number was used to represent the copy number of the
entire intact gene, and the gene was annotated with the
number of overlapping segments
Defining copy number gain and loss
The low-level copy number gain or loss of a gene was
defined by the log2 ratio of the copy number relative to
the average ploidy of the sample or diploid state with a
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threshold of ±0.4 respectively. We compiled a list of
genes with focal copy number alterations that were sig-
nificantly amplified (n = 273) or deleted (n = 820) in the
8 tumor types (Additional file 1: Fig. S8 and Table S12)
from the GISTIC 2.0 analysis from the TCGA Fire-
Browse website (http://firebrowse.org/). Using this set of
genes, we compared the proportion of genes that would
be classified as gain and loss when using different base-
lines (diploid state 2 or ASCAT predicted ploidy) for
PDX models listed in Additional file 1: Table S12.
Comparison of copy number alterations with gene
expression
Using annotations from the Cancer Gene Census re-
source [57] we analyzed the relationship between copy
number alterations and gene expression using a list of
23 oncogenes that are commonly amplified in cancers
and a list of 40 tumor suppressor genes that are com-
monly deleted in cancers. These genes were classified
into copy number states of high-level loss (log2(CN/
ploidy) < − 1), normal (− 1 ≤ log2(CN/ploidy) ≤ + 1) and
high-level gain (log2(CN/ploidy) > + 1). The expression
fold change of each gene was calculated as the
log2(TPM+ 1) relative to the mean expression across
PDX samples with a stringent normal copy number state
(− 0.4 ≤ log2(CN/ploidy) ≤ 0.4). The significance of ex-
pression changes of each gene for the entire PDX re-
source with copy number gain or loss relative to the
normal state was calculated using the Student’s t-Test.
Comparison between PDX and TCGA data
Somatic mutations
We calculated the distribution of mutational load (num-
ber of non-silent, coding mutations in exonic regions
per sample) of the CTP genes for 6 tumor types with at
least 10 models in the PDX resource (colorectal cancer,
lung adenocarcinoma, lung squamous cell carcinoma,
melanoma, bladder carcinoma and triple-negative breast
cancer, Additional file 1: Table S5). MAF files for som-
atic mutations based on whole-exome sequencing of the
TCGA samples of 6 tumor types [58–62] were obtained
from TCGA Data Portal and were used to compute the
mutation frequency for CTP genes only. The Fisher’s
exact test was used to test the significance of overlap of
mutated genes between the PDX resource and TCGA
patient cohorts for each tumor type. The genes in each
PDX resource were considered if they were mutated in
at least one sample, while the genes in each TCGA
tumor cohort were considered if they were mutated with
at least 5% frequency, due to a much larger sample size.
Gene expression
6 tumor types with at least 10 models in the PDX re-
source were selected for comparison with TCGA
(colorectal cancer, lung adenocarcinoma, lung squamous
cell carcinoma, melanoma, bladder carcinoma and
triple-negative breast cancer, Additional file 1: Table
S10). The scaled estimate (TPM× 10− 6) from the RNA-
Seq data of 6 tumor types in TCGA [58–63] were
obtained from the TCGA FireBrowse website (http://
firebrowse.org/). Non-expressed genes across all tumor
types were removed (log2(TPM+ 1) < 2), and the top
1000 most varying genes based on the variance of their
z-scores of log2(TPM+ 1) across all tumor types were
selected to cluster the TCGA samples by hierarchical
clustering. These 1000 most varying genes were inter-
sected, by common gene symbols, with the PDX expres-
sion data. The symbols of genes that mapped to multiple
genomic locations were removed, leaving 993 overlap-
ping genes. These 993 genes were then used to cluster
the PDX samples by hierarchical clustering. The fre-
quencies of over-expression and under-expression of
each gene is defined by the z-scores of log2(TPM+ 1) of
> + 1 and < − 1 respectively. Correlation of the gene ex-
pression frequencies in each tumor type was computed
using Pearson correlation. The differential gene expres-
sion of each tumor type compared to all other tumor
types was computed using limma and edgeR based on
expected counts from RSEM with TMM-normalization
and voom transformation [64, 65]. Up-regulated (ad-
justed p-value < 0.05, log (fold change) > 1) or down-
regulated (adjusted p-value < 0.05, log (fold change) < −
1) genes were obtained for the PDX resource and TCGA
patient cohorts separately. The significance of overlap of
each set of genes between PDX and TCGA RNA-Seq
data was determined using hypergeometric p-value.
Copy number alterations
Eight tumor types with at least 10 models in the PDX re-
source (colorectal cancer, lung adenocarcinoma, lung
squamous cell carcinoma, melanoma, glioblastoma mul-
tiforme, bladder carcinoma, triple-negative breast cancer
and ovarian carcinoma, Additional file 1: Table S12) se-
lected to compare with corresponding primary tumors
in the TCGA [58–63, 66–68]. For PDX samples, the
low-level copy number gain or loss of a gene was de-
fined by the log2 ratio of the copy number relative to the
average ploidy of the sample (or copy number state 2)
with a threshold of ±0.4 respectively. The amplification
or deletion calls of each gene for the TCGA samples
were provided (loss = − 1, normal = 0, gain = 1) by Fire-
Browse (http://firebrowse.org/). Using the list of genes
with focal copy number alterations that were signifi-
cantly amplified (n = 273) or deleted (n = 820) in the 8
tumor types from the GISTIC 2.0 analysis from the
TCGA FireBrowse website, we calculated the copy num-
ber gain and loss frequencies of these genes for each
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tumor type in the PDX resource and TCGA cohorts
using the respective gain and loss calls.
Results
Somatic point mutation and indels
A graphical overview of the workflow for calling somatic
mutations and indels in PDX tumors is provided in
Fig. 2a and b.
Preprocessing and removal of mouse reads
Human and mouse DNA reads were classified using
Xenome [16], which has a reported performance of >
90% correct classification of mouse and human reads
[69]. Only human reads were used for subsequent vari-
ant calling. The percentage of mouse reads identified in
the engrafted tumors had a median value of 5.30%
(range: 0.00163–65.1%; Fig. 2c). Using simulated sequen-
cing datasets on the JAX Cancer Treatment Profile™
(CTP) panel [31], we verified that omitting the Xenome
step for filtering the mouse reads resulted in many more
FP variant calls (Fig. 3a; Additional file 2: Table S1). The
FPs were due to the alignment of the mouse sequence
reads to the human reference genome with mismatches
that were subsequently called as variants with low-
quality scores (QD). While the default thresholds for
GATK hard filtering parameters [40] removed a large
proportion of the FPs, applying Xenome to filter for
human reads yielded higher precision and improvement
in recall. Also, Xenome filtering maintained the correl-
ation between the predicted versus actual allele frequen-
cies, which would otherwise decrease with higher mouse
contamination (Additional file 1: Table S2).
Filtering germline variants
Based on range of allele frequencies identified in se-
quences of normal human blood samples (Additional file
1: Text S1), the variants in each PDX tumor with an
allele frequency of 40–60% or > 90%, and present in ei-
ther public germline databases or our list of putative
germline variants (Additional file 1: Table S3), were fil-
tered out as germline variants. This was a more conser-
vative approach given that these known germline
variants in regions of copy number alterations where the
ratio of both alleles was not balanced would not be fil-
tered. Figure 3b shows that the germline filters reduced
the estimated somatic mutational load in the PDX tu-
mors (Additional file 1: Table S5) by about four-fold
(Additional file 1: Table S4).
Filtering false positives due to systematic errors
Putative somatic mutations with no known effects in
cancer that recur across large numbers of PDX samples
are potential FPs arising from reference human genome
assembly errors, sequencing errors, or alignment errors
in low mappability regions [70]. To detect these putative
FPs, we filtered out the variants at loci that were recur-
rently mutated in ≥25% (see Methods) of PDX tumors
(Fig. 2d). The distribution of tumor types for each of
these recurrently mutated positions (n = 52) was highly
similar to the overall distribution of tumor types in the
PDX resource with Pearson correlation coefficient > 0.9
(Additional file 1: Figure S2). This implies that these
mutations were systematic errors and were not explicitly
selected for in any tumor type, and thus, likely do not
contribute to tumor biology or treatment response.
While there was a negligible reduction in the overall
mutational load after filtering highly recurrent variants,
the filtering impact was notable for several known
cancer-related genes (e.g., ERBB4 and MUC16) (Fig. 2d,
Fig. 3b and Additional file 1: Table S4).
Rescuing false negative variants
To address the balance of false positive and false nega-
tive mutation calls, we “rescued” single nucleotide vari-
ants and indels that were initially filtered out as
germline using curated annotations available in the JAX
Clinical Knowledgebase (CKB, https://ckbhome.jax.org/)
[46, 47] (Additional file 1: Text S1, Additional file 1:
Table S4). Overall, 127 unique variants from 52 genes
(1.03% of the total and 2.21% of the filtered unique vari-
ants detected by the CTP platform) were rescued from
381 PDX tumors. Nine of these mutations were experi-
mentally validated to be present in the PDX model (Fig.
3c). Almost all were initially filtered as germline events,
as many well-known actionable cancer mutations (e.g.,
BRAF V600E and KRAS G12C) are present in the
dbSNP database and occurred at frequencies that fell
within our exclusion criteria. Two EGFR indels that were
not called by GATK initially, but that were detected by
Pindel were rescued as they were annotated clinically
relevant.
PDX somatic mutation workflow benchmarking
The benchmark testing of our somatic mutation work-
flow on a simulated dataset demonstrated high F1 score
in variant calling, with high precision and an insignifi-
cant compromise on the recall (Fig. 3a, Additional file 2:
Table S1 and Text S5). We observed that the allele fre-
quencies of the true positive (TP) variants correlate well
(Pearson correlation coefficient > 0.99) with the input al-
lele frequencies for all samples (Additional file 1: Figure
S3 and Table S2). Although the estimated allele frequen-
cies were lower than the true allele frequencies, this dif-
ference was marginal and could be attributed to the
reads carrying the variants being classified as non-
human reads by Xenome, or not mapped to the genome.
Moreover, all (20 out of 20) clinically relevant mutations
experimentally validated or clinically reported in the
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corresponding patient tumors were detected in the PDX
tumors (Fig. 3c).
Gene expression analysis in PDXs
A graphical overview of the workflow for gene expres-
sion analysis of PDX tumors is provided in Fig. 4a.
Identifying EBV-associated PDX lymphomas by RNA-Seq
expression data
Immunohistochemistry (IHC) for human CD45 is the
primary screen for EBV-associated lymphomas in the
JAX PDX Resource and is performed as one component
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Fig. 2 A multi-step variant filtering and “rescue” strategy to accurately identify somatic mutations in PDX tumors. a Overview of the PDX variant
calling workflow for engrafted tumors in the absence of paired-normal tumor samples and in the presence of mouse stroma. (see Methods for
details). b Overview of the filter and rescue strategy used in the variant calling workflow for JAX PDXs. MTB: Mouse Tumor Biology Database, RD:
Read depth, AF: Allele-frequency, FP: False positives, CKB: JAX Clinical Knowledgebase. c Proportion of mouse reads classified by Xenome for CTP
and RNA sequencing data across all PDX models. d The recurrent frequencies of the mutated positions (after germline filtering) for various genes
that were found to be recurrent in more than 25% of PDX samples. These were identified as additional false positive variants due to sequencing
errors or mapping issues
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Fig. 3 (See legend on next page.)
Woo et al. BMC Medical Genomics           (2019) 12:92 Page 10 of 19
also observed that EBV-associated lymphoma tumors
display a distinct and highly reproducible expression pat-
tern (Additional file 1: Text S2 and Figure S5). We im-
plemented a 48-gene expression signature based on the
most differentially expressed genes between EBV-
associated lymphomas and non-EBV-associated tumors
(Additional file 1: Table S6). This classifier was able to
effectively distinguish PDX tumors that were either
EBV-transformed from non-lymphoma PDX tumors or
originated from human lymphomas (Fig. 4b). Overall,
8.5% (32 out of 376) of the non-lymphoma PDX samples
with RNA-Seq data in the PDX resource progressed to
EBV-associated lymphomas.
Copy number alterations (CNA) analysis in PDXs
A graphical overview of the workflow for calling copy
number alterations in PDX tumors is provided in Fig. 5a.
Effect of mouse DNA on CNA calls
We studied the effect of mouse contamination on array
data by hybridizing DNA of the PDX host strain,
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (aka, NSG) mouse
strain from The Jackson Laboratory (strain 005557), on
the human SNP array. The signal intensity from mouse
DNA was negligible (Additional file 1: Figure S6). Sam-
ples with higher mouse content were more likely to fail
the standard array quality control, due to the lower
amount of human DNA to give sufficient probe signal,
thus enabling samples with substantial mouse contamin-
ation to be screened out.
Absence of matched non-tumor to call somatic copy
number alterations
We developed a single-tumor CNA analysis method, by
normalizing the SNP array signal intensity of the tumor
sample with that of HapMap [55, 71] samples of the
same sex. For the PDX samples with paired normal sam-
ples (n = 9), we observed the overall high similarity be-
tween the segmented copy number profiles analyzed
with and without the paired-normal sample (Additional
file 1: Figure S7). The gene-based log2(total CN/ploidy)
showed good correlation between the single-tumor and
tumor-normal CNA analysis (Pearson correlation >
0.81), with 8 out of 9 PDX samples correlating > 0.93
(Fig. 5a and Additional file 1: Table S7), indicating that
the single-tumor CNA analysis was robust.
Establishing the appropriate baseline to call copy number
gains and losses
Due to aneuploidy in cancer genomes, we analyzed the
effects of using different “normal” states to compute
copy number gains and losses using a list of significantly
amplified and deleted genes from TCGA (Additional file
1: Fig. S8, Additional file 2: Table S13). When the overall
cancer genome ploidy was used as the baseline, we
observed that a larger proportion of the significantly
amplified and deleted genes were called as copy number
gains and losses among the PDX samples respectively
(Additional file 1: Figure S9). However, a large fraction
of both significantly amplified and deleted genes were
classified as amplified when copy number alterations
were calculated relative to the diploid state, indicating
that calling copy number changes relative to the diploid
state could classify gain and loss genes incorrectly in the
PDX samples. While the average ploidy might not be es-
timated consistently across the tumor samples for the
same model, the copy number changes relative to overall
cancer genome ploidy remained consistent (Fig. 5b and
Additional file 1: Figure S7).
Effects of copy number alterations on expression changes
We observed that the estimated copy number gains and
losses of known oncogenes (n = 23) and tumor suppres-
sor genes (n = 40) [57], relative to the average ploidy per
PDX sample, generally results in expression changes in
the same direction as the copy number change (Add-
itional file 1: Table S8) [12, 72, 73]. In a subset of PDX
samples for which both expression and copy number
data were available (n = 194), the over and under-
expression were computed relative to the “normal”
(See figure on previous page.)
Fig. 3 The PDX somatic mutation calling workflow improved the accuracy of predicting somatic mutations in engrafted tumors. a Benchmarking
of the CTP variant calling workflow using 45 simulated sequencing datasets from different samples, sequence coverages, and mouse DNA
content (Additional file 1: Table S2) using precision, recall and F1 score (see Methods) based on the input variants for each sample. Complete:
variant calling pipeline with all steps included; NoXenome: variant calling pipeline with Xenome omitted; all: all variants called by the pipeline;
pass: variants annotated as “PASS” in the pipeline which pass the hard filters, minimum read depth and minimum alternate allele frequency of
the variant. b Distribution of mutational load per sample of non-silent coding somatic mutations for genes included on the CTP panel based on
exome sequencing of TCGA samples and CTP-panel sequencing of PDX models. TCGA somatic: TCGA somatic mutations reported in maf files;
PDX: all variants annotated as “PASS” (pass the hard filters, minimum read depth and minimum alternate allele frequency of the variant); PDX filter
germline: all variants annotated as “PASS” and filtered from putative germline variants; PDX filter germline & FP: all variants annotated as “PASS”
and filtered from putative germline variants and recurrent false positives. (LUAD: lung adenocarcinoma, LUSC: lung squamous cell carcinoma,
Colorectal: colon and rectal cancer, TNBC: triple-negative breast cancer, BLCA invasive: muscle invasive bladder cancer). c Mutations identified in
patient lung tumors that were retained in engrafted PDX tumors. Some of these variants were initially filtered out of the variant call analysis but
subsequently reinstated using the variant rescue protocol (Additional file 1: Figure S2)
Woo et al. BMC Medical Genomics           (2019) 12:92 Page 11 of 19
expression of each gene estimated by the average ex-
pression in samples with normal copy number state.
While this approach did not account for all mecha-
nisms of gene regulation, we were able to better esti-
mate the normal expression for genes compared to
using the mean expression (z-score) across all tumor
types, which could be biased for frequently aberrated
genes such as MYC, which tends to be frequently
amplified and over-expressed across many tumor
types [74, 75]. Most of these genes show significant
over-expression with copy number gain and signifi-
cant under-expression with copy number loss across
the PDX samples (p < 0.05) (Fig. 5c, Additional file 1:
Figure S10 and Text S3). These results support using
overall cancer genome ploidy as the baseline to call
copy number gain and loss.
Comparison of genomic and transcriptomic profiles of
PDX models and TCGA patient tumors
Because we lacked paired-normal samples for most
models in the JAX PDX resource, we were unable to ex-
perimentally validate the somatic mutations predicted by
our workflows. As an alternative approach to validation,
we compared the genomic and transcriptomic profiles
for the JAX models to data for the same tumor type
available from TCGA and assessed the overall concord-
ance of patterns in mutation frequency, gene expression,
and copy number alterations.
Frequently mutated genes in primary patient tumors in
TCGA are detected in the PDX resource
The distribution of somatic coding non-silent mutational
load of the CTP genes for each tumor type was
a
b
Fig. 4 Expression profiling and identification of EBV-associated lymphomas from PDX RNA sequencing data. a Overview of the PDX RNA-Seq
workflow (see Methods for details). b Distribution of lymphoma classification scores of PDX tumors
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comparable between PDX and TCGA (Fig. 6a). Despite
the much smaller sample size for each PDX tumor type,
we observed a higher mutational load in colorectal can-
cer and melanoma among other tumor types, which is
consistent with TCGA. Given that there were more sam-
ples in the TCGA cohorts, we compared the genes that
were mutated at 5% frequency with genes that were mu-
tated in at least one sample within the same tumor type
in the PDX resource. Almost all genes mutated at high
frequencies in TCGA tumors were mutated in PDX tu-
mors, with significant p-values (p < 1 × 10− 4) by Fisher’s
exact test (Fig. 6b, Additional file 1: Table S9). These
a
b c
Fig. 5 Somatic copy number gain and loss profiling from PDX SNP array data. a Overview of the copy number alteration and loss of heterozygosity
prediction workflow for SNP array data from PDX tumors (see Methods for details). b Comparison of copy number for ovarian cancer PDX TM00327
relative to the estimated overall cancer genome ploidy of the PDX sample or the diploid state between analyses with and without paired-normal. The
log2(CN/ploidy) gives the best agreement for comparing copy number analyzed with and without paired-normal. (CN-2: copy number difference relative
to diploid state; CN/2: copy number ratio relative to diploid state, CN-ploidy: copy number difference relative to overall cancer genome ploidy, CN/ploidy:
copy number ratio relative to overall cancer genome ploidy). c Mean expression fold change of genes with normal copy number, copy number gain
(log2(CN/ploidy) > 1) and copy number loss (log2(CN/ploidy) <− 1) state for a selected list of known oncogenes that are amplified in cancers and for
known tumor suppressor genes that are deleted in cancers from the Cancer Gene Census [57]. Over-expressed and under-expressed genes marked with *
indicates significant differences in expression fold change with copy number gain or loss state respectively relative to the normal state across all
PDX samples
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results indicate that the key drivers by mutation within
each cancer type are preserved in PDX tumors.
Expression signatures of primary patient tumors in TCGA
are recapitulated in the PDX resource
The top 1000 most varying genes across 6 TCGA tumor
types measured by the variance of expression z-scores
(Additional file 1: Table S10) were able to independently
cluster both TCGA samples and the PDX samples by their
tumor types (Fig. 6c). We observed that clusters of genes
that were highly expressed in specific tumor types in
TCGA were recapitulated in the PDX expression data
(hypergeometric p-value < 1 × 10− 8), which demonstrated
the replicability of TCGA expression signatures in the
PDX resource. The frequencies of over- and under-
expression for the top-varying genes for each tumor type
displayed better correlation for the same tumor type for
PDX versus TCGA compared to other tumor types (Fig.
6d). The varying level of concordance between different
tumor types in TCGA data was also maintained in the
PDX versus TCGA comparison (Additional file 1: Figure
S11). Alternatively, the differentially expressed genes of
each tumor type versus all other tumors within the TCGA
or PDX samples displayed significant overlaps (p < 1 × e−
6), despite different sample sizes and the different propor-
tion of tumor types (Additional file 1: Table S11).
Copy number profiles of primary patient tumors in TCGA
are recapitulated in the PDX resource
The frequency of genome-wide copy number alterations
for each tumor type in the PDX resource (Additional file
1: Table S12 and Fig. S12A) was similar to the primary
tumors in TCGA (Additional file 1: Fig. S12B). More-
over, the PDX tumors had the highest correlation in gain
and loss frequencies of significantly amplified and de-
leted genes for the same tumor type in TCGA compared
to other tumor types (Fig. 6e and Additional file 1: Fig-
ure S13A). The varying levels of correlation between dif-
ferent tumor types were preserved between the TCGA
versus TCGA tumors and the TCGA versus PDX tumors
(Fig. 6e and Additional file 1: Fig. S14). Consistent with
the earlier observations, there was a weaker concordance
with TCGA data when amplification and deletion were
called relative to the diploid state (Additional file 1: Fig-
ure S13B).
Discussion
Genomic data analysis workflows designed to call som-
atic mutations (SNVs, indels), copy number alterations
and gene expression from PDX sequencing or array data
require balancing sensitivity and specificity [25, 70], es-
pecially when paired normal samples for engrafted tu-
mors are not available. Using genomic and
transcriptomic data from models in the JAX PDX
resource, we developed and tailored data analysis work-
flows to reliably identify true somatic mutations, copy
number alterations, and expression changes using gen-
omic and transcriptomic data from PDX tumors that
lack paired non-tumor samples. Key elements of our
analysis guidelines and recommendations are summa-
rized below.
We recommend using multiple data sources for germ-
line variants and cancer relevant variants to fine-tune
workflows for calling somatic mutations to achieve a
reasonable balance of false-negative and false positives.
Variant calling pipelines should be re-run periodically as
new data about germline and cancer-relevant variants
become available. Our major recommendations for data
analysis workflows for calling somatic mutations for
PDX tumors in the absence of paired-normal samples
include the following:
 Remove mouse reads with Xenome (or equivalent)
[16, 69, 76, 77] to eliminate variants called from
mouse reads that map to highly conserved regions
of the human reference genome.
 Optimize quality thresholds (variant read depth and
allele frequencies, and various sequencing and
alignment quality values) to filter for high quality
variant calls for any given capture panel and
sequencing coverage.
 Adjust quality filters to detect low frequency
variants (> 5%) with high confidence in order to
detect clinically-relevant variants that are present in
minor clones.
 Filter variant calls to remove those that are likely
germline variants [43–45] to improve somatic
mutation calling.
 Filter highly recurrent (> maximum somatic
mutation frequency) mutations to remove false
positives arising from sequencing or analysis-related
errors.
 Reinstate (rescue) variants with putative clinical
relevance [46, 78–81] that meet quality thresholds
but are initially filtered out as germline or highly
recurrent. This “variant rescue” process will likely
also reclaim germline variants that are associated
with cancer susceptibility and treatment response
[82, 83] which may be important for selecting PDX
models for dosing studies.
We recommend using publicly available data sets to
generate a proxy for sex-matched normal samples in
order to estimate copy number alterations in an
engrafted PDX tumors. Our major recommendations for
data analysis workflows for estimating copy number al-
terations by SNP arrays for PDX tumors in the absence
of paired-normal samples include the following:




Fig. 6 Comparison of somatic genomic and transcriptomic profiles between JAX PDX resource and TCGA tumor cohorts. a Distribution of mutational load of
non-silent coding somatic mutations for genes on the CTP panel based on exome sequence data for TCGA samples and CTP panel-based sequence data for
JAX PDX models (all filters included). (LUAD: lung adenocarcinoma, LUSC: lung squamous cell carcinoma, COADREAD: colorectal adenocarcinoma, Colorectal:
colon and rectal cancer, TNBC: triple-negative breast cancer, BLCA: urothelial bladder carcinoma, BLCA invasive: muscle invasive bladder cancer, SKCM: skin
cutaneous melanoma, GBM: glioblastoma multiforme). b Overlap of CTP panel genes that have non-silent coding somatic mutations with > 5% mutation
frequency in TCGA data with genes that have at least one non-silent coding somatic mutation in PDX CTP data (all filters and rescue of clinically relevant
variants included) for each tumor type. Fisher’s exact test (Additional file 1: Table S9) was used to compute the significance of the overlap. c Hierarchical
clustering of z-score of expression (log2(TPM+1)) of top 1000 most varying genes of TCGA RNA-Seq samples across different tumor types. The same set of
genes (omitting non-expressed genes) was used as input for unsupervised hierarchical clustering of PDX models for all tumor types represented in the JAX
resource. Gene sets identified as having high expression in specific tumor types had significant overlap between TCGA and PDX samples. d Correlation
between PDX models and TCGA samples of over-expressed (z-score of log2(TPM+1) > 1, green) or under-expressed (z-score of log2(TPM+1) <− 1, orange)
genes across multiple tumor types. e Correlation between PDX and TCGA tumors for the frequency of copy number gain (red) or loss (blue) of selected genes
frequently amplified or deleted in TCGA tumors as predicted by GISTIC
Woo et al. BMC Medical Genomics           (2019) 12:92 Page 15 of 19
 Normalize SNP array signal intensity with a large
number of normal samples [55, 71] that correspond
to the sex of the patient associated with the PDX
model.
 Estimate copy number gains and losses using copy
number ratio relative to overall cancer genome
ploidy
Although not evaluated for the work reported here,
data analysis methods have been developed by other re-
search groups to estimate copy number alterations in
absence of paired-normal samples from whole-exome or
whole-genome sequence data [84–86]. Comparison of
these methods to CNA evaluation by SNP arrays will re-
quire additional genome characterization for the PDX
tumors in the JAX repository.
We recommend using gene expression data from
engrafted tumors for both quality assurance of PDX
models in addition to comparing gene expression levels.
Our major recommendations for data analysis workflows
for comparing gene expression levels for PDX tumors in
the absence of paired-tissue RNA include the following:
 Screen for EBV-transformed lymphomas using
lymphoma expression classifier score in addition to
a primary screen of paraffin embedded tumor sam-
ples using immunohistochemistry for human CD45+
cells.
 Use mean expression across samples of all tumor
types (z-score) or average expression across samples
with “normal” copy number state for comparison of
gene expression levels.
The availability of RNA-Seq data for engrafted tumors
provides an opportunity for predicting fusion genes and
various software tools are available for this purpose [87,
88]. Benchmarking fusion gene prediction methods for
engrafted tumors is planned for a future extension of
our PDX analysis workflows.
To assess the quality of our genomic characterization
workflows, we compared the results of our workflows
for PDX tumors with data from TCGA. Overall, our ana-
lysis results demonstrated that patterns of frequently
mutated genes, copy number alterations, and gene ex-
pression were comparable in PDX and TCGA samples
of the same tumor type. Using colorectal cancer as an
example, we demonstrated that pathways known to be
perturbed in this cancer were altered consistently in
PDX and TCGA tumors [58] (Additional file 1: Text S6
and Fig. S15), with similar combinations of alterations
occurring at comparable frequencies.
One persistent difference in PDX and TCGA samples
was in the predicted mutational load of comparable tu-
mors. Despite implementing multiple filters to remove
putative germline and other FP mutations, the mutation
rates calculated for the JAX PDX tumors are higher than
data for corresponding tumors from the TCGA (Add-
itional file 1: Text S4). This could be because PDX
tumors were sequenced at a higher coverage compared
to TCGA tumors and/or because germline variants were
not completely filtered out in the PDX samples. Another
possible reason for this difference that many of the
human tumor samples used to generate PDX models
were from metastatic lesions and patients with prior
treatment whereas many of the tumor samples in TCGA
represent early stage tumors which are treatment naive.
Overall, 51.0 and 31.4% of the PDX models in the JAX
resource are late-stage and high-grade tumors respect-
ively, while 32.1% of TCGA tumors [89] (Additional file
1: Table S5) are late-stage tumors. These PDX tumors
are thus expected to harbor more mutations due to
tumor evolution [90, 91]. Further, previous studies have
noted that PDX engraftment success is higher for late-
stage tumors that are likely to have more aggressive phe-
notypes than for early-stage tumors [92, 93]. As such, it
is possible tumors from PDXs harbor more mutations
due to a bias in engraftment success.
Conclusions
In conclusion, the bioinformatics analysis workflows and
guidelines (https://github.com/TheJacksonLaboratory/
PDX-Analysis-Workflows) that we have developed for
the analysis of genomic data generated from PDX tu-
mors lacking paired non-tumor tissue result in accurate
detection of somatic alterations in PDX models. We
demonstrate the effectiveness of our workflows by valid-
ating with simulated data. In addition, we show that
there is high concordance of the genomic and transcrip-
tomic profiles of the PDX models in the JAX PDX re-
source with relevant tumor types from The Cancer
Genome Atlas (TCGA).
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